Early phase clinical trials
Naam: Emilie van Brummelen
Vooropleiding: Pharmacy (Utrecht)
Loopbaan: Emilie van Brummelen (1989) graduated from the Honours Programme of Pharmacy at Utrecht University in 2013. After that, she worked on the early phase clinical development of targeted anticancer agents including pembrolizumab, cergutuzumab amunaleukin and MEK/panHER inhibitors at the Netherlands Cancer Institute in Amsterdam. This resulted in a PhD thesis on the early phase clinical development of targeted anticancer agents in 2017. Since 2017, she has been a board-certified clinical pharmacologist at the Dutch Society of Clinical Pharmacology and Biopharmacy. Emilie joined CHDR in 2018 and as of January 1st 2019 she holds a position as senior clinical scientist with focus on immuno-oncology, neuromuscular diseases and design of early phase clinical trials.
Beroep: Senior Clinical Scientist
De workshop: The workshop is about Early phase clinical trials